Form 4: Avidity CSO Disposes Shares, Options in Novartis Merger

Avidity Biosciences' Chief Scientific Officer, W. Michael Flanagan, disposed of common stock and stock options as part of the previously announced merger with Novartis.

Summary

• W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences, Inc., reported the disposition of securities on February 27, 2026.
• Disposed of 150,365 shares of common stock, which included shares issuable upon settlement of previously reported restricted stock units.
• Disposed of multiple stock options with exercise prices ranging from $6.57 to $31.42.
• All dispositions were made pursuant to the Agreement and Plan of Merger, dated October 25, 2025, between Novartis AG, Ajax Acquisition Sub, Inc., and Avidity Biosciences, Inc.
• Stock options were exchanged for a cash payment equal to the excess of the merger consideration of $72.00 per share over their respective exercise prices.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive indicator, as the insider's disposition of securities is a direct result of a successful merger, implying a favorable outcome for shareholders involved in the acquisition.

Positives

• The disposition of stock options at a premium to their exercise price, based on a $72.00 merger consideration, indicates a profitable outcome for the option holder.
• The transactions are a direct result of a merger agreement with Novartis AG, suggesting a successful strategic outcome for Avidity Biosciences and its shareholders.

Future Outlook

This filing reports past transactions related to a merger and does not provide forward-looking statements or guidance from the company.

Industry Context

StockSavvy.ai notes that the disposition of securities by a Chief Scientific Officer following a merger agreement with a major pharmaceutical company like Novartis AG is a standard procedural step. This transaction reflects the finalization of the acquisition, indicating a successful exit for Avidity Biosciences and its shareholders, aligning with a trend of larger pharmaceutical companies acquiring innovative biotech firms for pipeline expansion.

Comparison to Industry Standards

• StockSavvy.ai observes that the merger consideration of $72.00 per share for Avidity Biosciences, leading to the disposition of options at a premium, is indicative of a strong valuation for a biotech company with promising RNA-based therapeutics.
• Similar acquisitions in the biotech space, such as Gilead Sciences' acquisition of Immunomedics for $21 billion ($88 per share) or Bristol Myers Squibb's acquisition of MyoKardia for $13.1 billion ($225 per share), demonstrate the high value placed on innovative drug platforms.
• The $72.00 per share consideration for Avidity suggests a robust premium over the option exercise prices, reflecting the market's and acquirer's confidence in Avidity's technology and pipeline.

Stakeholder Impact

• Shareholders: Existing shareholders of Avidity Biosciences would receive the merger consideration of $72.00 per share, indicating a positive return if the acquisition price is at a premium.
• Employees: Employees holding stock options or restricted stock units would realize value from their equity holdings as part of the merger.

Next Steps

• Completion of the merger with Novartis AG, if not already finalized.
• Further insider transaction reports related to the merger as other executives and directors dispose of their holdings.

Key Dates

Recommendation

The filing indicates that Avidity Biosciences is being acquired by Novartis AG at a merger consideration of $72.00 per share. For existing shareholders, holding the stock until the merger's completion is the appropriate action to realize the agreed-upon acquisition price. For new investors, there is no actionable investment opportunity in Avidity Biosciences' stock as an independent entity, as its value is now tied to the merger consideration.

Keywords

Avidity Biosciences, RNAM, Novartis, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Common Stock, W. Michael Flanagan, Chief Scientific Officer, SEC Filing